Results 61 to 70 of about 2,749,589 (298)
Drug-resistant epilepsy: Definition, pathophysiology, and management
, 2023 There are currently >51 million people with epilepsy (PWE) in the world and every year >4.9 million people develop new-onset epilepsy. The cornerstone of treatment in PWE is drug therapy with antiseizure medications (ASMs).
Al Hail, Hassan +5 more
core +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objectives Focal cortical dysplasia (FCD) is the most common etiology of drug‐resistant epilepsy in children. Focal to bilateral tonic–clonic seizures (FBTCS) mark a high risk of drug‐resistant epilepsy and involve thalamocortical circuitry in their generation and propagation.
Hua Xie +8 more
wiley +1 more source
Augmenting and Assaying Nav1.1 Protein Quantity for Dravet Syndrome Therapy
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Dravet Syndrome (DS) is a developmental and epileptic encephalopathy predominantly caused by heterozygous loss‐of‐function variants in SCN1A, which encodes Nav1.1. Conserved upstream open reading frames (uORFs) in SCN1A were validated to regulate translation in reporter assays, demonstrating the therapeutic viability of increasing Nav1.1 from ...
Aiswarya Saravanan +7 more
wiley +1 more source
Frontiers in Veterinary Science, 2022 Epilepsy is a common neurological disorder affecting 0.6–0.75% of dogs in veterinary practice. Treatment is frequently complicated by the occurrence of drug-resistant epilepsy and cluster seizures in dogs with idiopathic epilepsy.
Sandra R. P. Kriechbaumer +12 more
doaj +1 more source
Stress regulation in drug-resistant epilepsy [PDF]
Epilepsy & Behavior, 2017 The prevalence of psychological distress, especially depressive and anxiety disorders, is higher in epilepsy than in other chronic health conditions. These comorbid conditions contribute even more than epileptic seizures themselves to impaired quality of life in patients with epilepsy (PWE).
Kotwas, Iliana +4 more
openaire +4 more sources
Safety and Efficacy of GLP‐1 Receptor Agonists in Adults With Epilepsy, Obesity, and Type 2 Diabetes
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Managing obesity in patients with epilepsy is complicated by the weight‐gaining properties of essential antiseizure medications (ASMs) such as valproate and pregabalin. We evaluated the safety and efficacy of initiating glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in this population.
Hyoshin Son +3 more
wiley +1 more source
Эпилепсия и пароксизмальные состоянияCurrently, the problem of effective therapy for drug-resistant epilepsy remains vastly relevant. The severity of drug-resistant epilepsy, remarkable negative social sequelae and sudden death in epilepsy pose a heavy burden on healthcare system.
A. M. Yakimov +6 more
doaj +1 more source
Clinical diagnostic features and surgical outcomes of mesial temporal lobe epilepsy
Вестник хирургии имени И.И. Грекова, 2023 Despite certain successes in the treatment of epilepsy, primarily associated with the active development of pharmacology, in 30% of cases, there is a resistant course, especially focal forms of temporal lobe epilepsy.
O. P. Subbotina +2 more
doaj +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background We aimed to identify the proportion of individuals with a confirmed diagnosis of childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE) who show a negative routine EEG (rEEG), and to determine the main factors associated with this finding.
Francesco Fortunato +7 more
wiley +1 more source
Эпилепсия и пароксизмальные состояния, 2023 Background. One of the main goals of rehabilitation programs is to improve the quality of life (QoL) of patients with various chronic diseases, including epilepsy.
E. А. Narodova +3 more
doaj +1 more source